ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer

Moonsun Jung1,2, Jixuan Gao1, Leanna Cheung1

  • 1Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW Australia, Kensington, New South Wales, Australia.

Insights

High expression of ATP-binding cassette subfamily C member 4 (ABCC4/MRP4) correlates with poor outcomes in ovarian cancer subtypes. Suppressing MRP4 reduced tumor growth and invasion, identifying it as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Epithelial ovarian cancer (EOC) is a heterogeneous disease with poor survival rates.
  • ATP-binding cassette (ABC) transporters, like ABCC4/MRP4, are implicated in drug resistance and cancer progression.
  • Targeting specific molecular pathways is crucial for developing effective EOC treatments.

Purpose of the Study:

  • To investigate the association of ABCC4/MRP4 expression with clinical outcomes in EOC subtypes.
  • To elucidate the biological function of ABCC4/MRP4 in endometrioid and serous EOC.
  • To evaluate ABCC4/MRP4 as a potential therapeutic target in EOC.

Main Methods:

  • Analysis of ABCC4/MRP4 expression in relation to patient prognosis.
  • siRNA-mediated suppression of MRP4 in EOC cell lines.
  • Assessment of cell growth, migration, and invasion following MRP4 knockdown.
  • Evaluation of drug sensitivity in MRP4-suppressed cells.
  • In vivo studies using patient-derived EOC cells.

Main Results:

  • High ABCC4/MRP4 expression is linked to poor prognosis in endometrioid EOC and a subset of serous EOC (high-MYCN profile).
  • MRP4 suppression reduced EOC cell growth, migration, and invasion, particularly in endometrioid and C5-like serous subtypes.
  • Knockdown of MRP4 increased sensitivity to MRP4 substrate drugs in endometrioid EOC cells.
  • In vivo, MRP4 suppression inhibited the growth of patient-derived EOC xenografts.

Conclusions:

  • ABCC4/MRP4 plays a significant role in the biology of Myc-associated ovarian tumors.
  • MRP4 is a potential therapeutic target for specific subtypes of epithelial ovarian cancer.
  • Targeting MRP4 may offer a novel strategy to improve treatment outcomes for EOC patients.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K